Rinvoq (upadacitinib) 15 mg, 28 tablets Rinvoq is used for approved indications including rheumatoid arthritis. International medicine delivery within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.
- Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment. - Pickup from Odesafree
- Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.
Delivery time
- Originator medicines: 5-7 days
- Generic medicines: 3-4 days
- Bank transfer to the settlement account after receiving the order
- Payment upon pickup in Odesa
Rheumatoid arthritis
Rinvoq® is indicated for the treatment of rheumatoid arthritis of medium and high degree of activity in adult patients, when an adequate response has not been obtained or there is intolerance to one or more antirheumatic drugs that modify the course of the disease (DMARDs - disease-modifying antirheumatic drugs).
Rinvoq® can be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
Rinvoq® is indicated for the treatment of active psoriatic arthritis in adult patients who have an inadequate response or intolerance to one or more antirheumatic drugs that modify the course of the disease. Rinvoq® can be used as monotherapy or in combination with methotrexate.
Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSA)
Rinvoq® is indicated for the treatment of active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation, confirmed by elevated C-reactive protein (CRP) and/or MRI findings, and with an inadequate response to nonsteroidal anti-inflammatory drug (NSAID) therapy.
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
Rinvoq® is indicated for the treatment of active ankylosing spondylitis in adult patients with an inadequate response to standard therapy.
Atopic dermatitis
Rinvoq® is indicated for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 years who are candidates for systemic therapy.
Ulcerative colitis
Rinvoq® is indicated for the treatment of moderate to severe active ulcerative colitis in adult patients with inadequate response, loss of response, or intolerance to standard therapy or biologics.
Crohn's disease
Rinvoq® is indicated for the treatment of Crohn's of moderate and severe activity in adult patients with inadequate response, loss of response or intolerance to standard therapy
or biological drugs.
